Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 217-226 |
| Journal | Breast cancer research and treatment |
| Volume | 176 |
| Issue number | 1 |
| Early online date | 10 Apr 2019 |
| DOIs | |
| Publication status | Published - 1 Jul 2019 |
Fingerprint
Keywords
- UT-Hybrid-D
Cite this
}
Pathologic complete response and overall survival in breast cancer subtypes in stage III inflammatory breast cancer. / Van Uden, Dominique J.P. (Corresponding Author); van Maaren, Marissa Corine; Bult, Peter; Strobbe, Luc J.A.; van der Hoeven, Johannes J.M.; Blanken-Peeters, C.F.J.M.; Siesling, Sabine ; de Wilt, Johannes H.W.
In: Breast cancer research and treatment, Vol. 176, No. 1, 01.07.2019, p. 217-226.Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Pathologic complete response and overall survival in breast cancer subtypes in stage III inflammatory breast cancer
AU - Van Uden, Dominique J.P.
AU - van Maaren, Marissa Corine
AU - Bult, Peter
AU - Strobbe, Luc J.A.
AU - van der Hoeven, Johannes J.M.
AU - Blanken-Peeters, C.F.J.M.
AU - Siesling, Sabine
AU - de Wilt, Johannes H.W.
N1 - Springer deal
PY - 2019/7/1
Y1 - 2019/7/1
N2 - Purpose To analyze the influence of hormone receptors (HR) and Human Epidermal growth factor Receptor-2 (HER2)-based molecular subtypes in stage III inflammatory breast cancer (IBC) on tumor characteristics, treatment, pathologic response to neoadjuvant chemotherapy (NACT), and overall survival (OS). Methods Patients with stage III IBC, diagnosed in the Netherlands between 2006 and 2015, were classified into four breast cancer subtypes: HR+/HER2− , HR+/HER2+ , HR−/HER2+ , and HR−/HER2− . Patient-, tumor- and treatment-related characteristics were compared. In case of NACT, pathologic complete response (pCR) was compared between subgroups. OS of the subtypes was compared using Kaplan–Meier curves and the log-rank test. Results 1061 patients with stage III IBC were grouped into subtypes: HR+/HER2− (N = 453, 42.7%), HR−/HER2− (N = 258, 24.3%), HR−/HER2+ (N = 180,17.0%), and HR+/HER2+ (N = 170,16.0%). In total, 679 patients (85.0%) received NACT. In HR−/HER2+ tumors, pCR rate was highest (43%, (p < 0.001). In case of pCR, an improved survival was observed for all subtypes, especially for HR+/HER2+ and HR−/HER2+ tumor subtypes. Trimodality therapy (NACT, surgery, radiotherapy) improved 5-year OS as opposed to patients not receiving this regimen: HR+/HER2− (74.9 vs. 46.1%), HR+/HER2+ (80.4 vs. 52.6%), HR−/HER2+ (76.4 vs. 29.7%), HR−/HER2− (47.6 vs. 27.8%). Conclusions In stage III IBC, breast cancer subtypes based on the HR and HER2 receptor are important prognostic factors of response to NACT and OS. Patients with HR−/HER2− IBC were less likely to achieve pCR and had the worst OS, irrespective of receiving most optimal treatment regimen to date (trimodality therapy).
AB - Purpose To analyze the influence of hormone receptors (HR) and Human Epidermal growth factor Receptor-2 (HER2)-based molecular subtypes in stage III inflammatory breast cancer (IBC) on tumor characteristics, treatment, pathologic response to neoadjuvant chemotherapy (NACT), and overall survival (OS). Methods Patients with stage III IBC, diagnosed in the Netherlands between 2006 and 2015, were classified into four breast cancer subtypes: HR+/HER2− , HR+/HER2+ , HR−/HER2+ , and HR−/HER2− . Patient-, tumor- and treatment-related characteristics were compared. In case of NACT, pathologic complete response (pCR) was compared between subgroups. OS of the subtypes was compared using Kaplan–Meier curves and the log-rank test. Results 1061 patients with stage III IBC were grouped into subtypes: HR+/HER2− (N = 453, 42.7%), HR−/HER2− (N = 258, 24.3%), HR−/HER2+ (N = 180,17.0%), and HR+/HER2+ (N = 170,16.0%). In total, 679 patients (85.0%) received NACT. In HR−/HER2+ tumors, pCR rate was highest (43%, (p < 0.001). In case of pCR, an improved survival was observed for all subtypes, especially for HR+/HER2+ and HR−/HER2+ tumor subtypes. Trimodality therapy (NACT, surgery, radiotherapy) improved 5-year OS as opposed to patients not receiving this regimen: HR+/HER2− (74.9 vs. 46.1%), HR+/HER2+ (80.4 vs. 52.6%), HR−/HER2+ (76.4 vs. 29.7%), HR−/HER2− (47.6 vs. 27.8%). Conclusions In stage III IBC, breast cancer subtypes based on the HR and HER2 receptor are important prognostic factors of response to NACT and OS. Patients with HR−/HER2− IBC were less likely to achieve pCR and had the worst OS, irrespective of receiving most optimal treatment regimen to date (trimodality therapy).
KW - UT-Hybrid-D
U2 - 10.1007/s10549-019-05219-7
DO - 10.1007/s10549-019-05219-7
M3 - Article
VL - 176
SP - 217
EP - 226
JO - Breast cancer research and treatment
JF - Breast cancer research and treatment
SN - 0167-6806
IS - 1
ER -